Spread of pancreatic cancer to the liver or lungs depends on plasticity of tumor cells

Pancreatic cancer often spreads, forming metastases in the liver or lungs. The prognosis is better for patients with metastases in the lungs. However, the organ that is more likely to be affected depends on the cancer cells' ability to alter their characteristics and shape - as a research team at the Technical University of Munich (TUM) has discovered.

Cells in a tissue or tumor establish contacts with other cells and assume a scale-like appearance. Cancer cells that form metastases, however, must first alter their shape and characteristics. They have to modify their metabolism and detach themselves from the cluster of cells making up the tumor. As a result, they become long and thin, which allows them to enter nearby blood vessels. They then use the bloodstream as a transport route to reach other organs and proliferate in tissue there.

The cells must then transform themselves once again. They have to re-establish contacts with other cells in order to cling to them, so to speak. Not all cancer cells possess this flexibility, technically known as plasticity. Dr Maximilian Reichert, lead author of the new study and research group leader in the Internal Medicine Unit II of TUM university hospital Klinikum rechts der Isar, discovered why this is the case and what consequences it has for the spread of pancreatic cancer. The findings were published in the journal Developmental Cell.

Liver or lungs - what is the decisive factor?

"We were able to show that the spread of pancreatic cancer to the liver depends on the plasticity of the cancer cells. If the cells are unable to establish cell-to-cell contacts, they are passively flushed into the lungs by the bloodstream, where they become lodged," Reichert explains. "This course of the disease is more favorable for patients, because lung tumors are easier to control."

The plasticity of a cancer cell depends crucially on the presence of a cell adhesion molecule: the protein E-cadherin. Located on the cell surface, it is responsible for cell-to-cell contacts. Using a mouse model, the research team discovered that the absence of E-cadherin results in pancreatic cancer cells spreading to the lungs but not to the liver.

When the protein was present and functional, the cancer cells were also able to invade the liver. The researchers believe that this is because the cancer cells are able to take hold in liver tissue and to colonize the organ due to close cell-to-cell contacts established with the help of E-cadherin. By altering the presence of E-cadherin, the research team was able to control the metastasis process in mice.

Epigenetic factors as cause

The research team discovered that these mechanisms are evidently controlled in the tumor by epigenetic programs. In the process, the genetic material (DNA) itself is not altered. Instead, chemical factors determine how strongly or weakly a section of DNA is read.

Together with colleagues at Klinikum rechts der Isar, the team led by Maximilian Reichert plans to investigate whether these epigenetic programs can be inhibited or are suitable targets for treatment. "The more we understand about the formation of metastases, the better we'll be able to influence the process. This is particularly important in the case of pancreatic cancer, because nearly all pancreatic cancer patients die as a result of metastases," as Reichert states.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New therapeutic target overcomes ovarian cancer immunotherapy resistance